A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Immunovant, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 18,136 shares of IMVT stock, worth $498,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,136
Previous 18,136 -0.0%
Holding current value
$498,921
Previous $478,000 4.18%
% of portfolio
0.0%
Previous 0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$31.31 - $44.19 $567,838 - $801,429
18,136 New
18,136 $764,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.